Compare
Puma Biotechnology, Inc. vs Anaptysbio, Inc vs Akebia Therapeutics, Inc. vs IDEAYA Biosciences, Inc.
| Latest fiscal year | Puma Biotechnology, Inc. PBYI | Anaptysbio, Inc ANAB | Akebia Therapeutics, Inc. AKBA | IDEAYA Biosciences, Inc. IDYA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $228.37M | $234.60M | $236.20M | $218.71M |
| Revenue growth (YoY) | -0.9% | +157.0% | +47.5% | n/m |
| Gross margin | 74.5% (computed) | n/a | 83.3% (computed) | n/a |
| Operating margin | 16.3% | 20.4% | 9.9% | -72.8% |
| Net margin | 13.6% | -5.6% | -2.3% | -52.0% |
| Net income | $31.11M | -$13.23M | -$5.34M | -$113.70M |
| EPS (Diluted) | $0.61 | -$0.46 | -$0.02 | -$1.28 |
| Operating cash flow | $41.80M | $19.70M | $67.99M | -$71.10M |
| Free cash flow | $41.73M | $19.61M | $67.70M | -$73.47M |
| Cash & equivalents | $29.64M | $238.20M | $184.84M | $112.83M |
| Total assets | $216.30M | $364.39M | $376.56M | $1.11B |
| Total liabilities | $85.96M | n/a | $343.95M | $86.39M |
| Shareholders' equity | $130.34M | $37.21M | $32.61M | $1.02B |
| Return on year-end equity | 23.9% | -35.6% | -16.4% | -11.1% |
| Shares outstanding | 50.41M | 28.02M | 265.42M | 87.80M |
Revenue, most recent five fiscal years
| Fiscal year | Puma Biotechnology, Inc. | Anaptysbio, Inc | Akebia Therapeutics, Inc. | IDEAYA Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $228.37M Ended 2025-12-31 | $234.60M Ended 2025-12-31 | $236.20M Ended 2025-12-31 | $218.71M Ended 2025-12-31 |
| 1 year earlier | $230.47M Ended 2024-12-31 | $91.28M Ended 2024-12-31 | $160.18M Ended 2024-12-31 | $7.00M Ended 2024-12-31 |
| 2 years earlier | $235.64M Ended 2023-12-31 | $17.16M Ended 2023-12-31 | $194.62M Ended 2023-12-31 | $23.39M Ended 2023-12-31 |
| 3 years earlier | $228.03M Ended 2022-12-31 | $10.29M Ended 2022-12-31 | $292.48M Ended 2022-12-31 | $50.93M Ended 2022-12-31 |
| 4 years earlier | $253.16M Ended 2021-12-31 | $63.17M Ended 2021-12-31 | $211.65M Ended 2021-12-31 | $27.94M Ended 2021-12-31 |